Abstracts tagged "IgG4 Related Disease"

Abstract Number: 2001 • ACR Convergence 2023
Burden of Metabolic Bone Disease in Patients with IgG4-Related Disease with and Without Autoimmune Pancreatitis
Guy Katz¹, Aubree McMahon¹, Grace McMahon¹, Isha Jha¹, Marcy Bolster², Ana Fernandes¹, Zachary Wallace³, Cory Perugino¹, John Stone⁴ and Yasmin Hernandez-Barco¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Concord, MA, ³Massachusetts General Hospital, Newton, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: Metabolic bone disease (MBD), including osteopenia and osteoporosis, is common in patients with inflammatory disorders, due to disease factors and glucocorticoid (GC) use, and…
Abstract Number: 0271 • ACR Convergence 2023
Successful Treatment of Refractory IgG4-Related Disease with Tofacitinib: Experiences from 7 Patients
Huaqun Zhu, Sumei Tang, Yun Li, Feng Sun, Yuzhou Gan and Hua Ye, Peking University People’s Hospital, Beijing, China
Background/Purpose: Our observational cohort study aimed at assessing the effectiveness and safety of the Janus kinase (JAK) inhibitor tofacitinib in refractory IgG4-Related Disease (IgG4-RD).Methods: Seven…
Abstract Number: 2089 • ACR Convergence 2023
Social Listening Analysis of IgG4-Related Disease Social Media Discussions
Esteban Rivera¹, Kelly Gavigan², Daniel Hernandez³, Maria Picone⁴, Angeni Cordova⁴, Lauren Dougherty⁴, Kristina Davidson⁵, Brian LaMoreaux⁶, Anthony Amatucci⁷ and W. Benjamin Nowell⁸, ¹Global Healthy Living Foundation, Long Island City, NY, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, St. Johns, FL, ⁴TREND Community, Philadelphia, PA, ⁵Horizon Therapeutics, Dublin, Ireland, ⁶Horizon Therapeutics, Deerfield, IL, ⁷Horizon Therapeutics, Cambridge, MA, ⁸Global Healthy Living Foundation, Nyack, NY
Background/Purpose: Immunogobulin G4-Related Disease (IgG4-RD) is a rare chronic immune-mediated fibroinflammatory disorder that often manifests with tumor-like masses and/or enlargement of multiple organs. In order…
Abstract Number: 0273 • ACR Convergence 2023
Disease Characteristics and Pancreatic Damage in IgG4-Related Disease with Pancreatic Involvement
Guy Katz¹, Liam Harvey², Yasmin Hernandez-Barco¹, Ana Fernandes¹, Grace McMahon¹, Isha Jha¹, Zachary Wallace³, Cory Perugino¹ and John Stone⁴, ¹Massachusetts General Hospital, Boston, MA, ²Frank H. Netter School of Medicine at Quinnipiac University, New Haven, CT, ³Massachusetts General Hospital, Newton, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic immune-mediated fibroinflammatory disease that can affect nearly every organ system. Autoimmune pancreatitis (AIP) is among the most common…
Abstract Number: 0330 • ACR Convergence 2023
Patient-Reported Experiences and Comorbidities in Patients with IgG4-Related Disease with and Without Pancreatic Involvement
Liam Harvey¹, Guy Katz², Yasmin Hernandez-Barco², Ana Fernandes², Aubree McMahon², Grace McMahon², Isha Jha², Zachary Wallace³, Cory Perugino² and John Stone⁴, ¹Frank H. Netter School of Medicine at Quinnipiac University, New Haven, CT, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Newton, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: IgG4-Related Disease (IgG4-RD) is a systemic immune-mediated disease that commonly involves the pancreas in the form of autoimmune pancreatitis (AIP). Despite being one of…
Abstract Number: 0706 • ACR Convergence 2023
Aortitis and Periaortitis Spectrum in 135 Patients from a Single Referral Centre
Fernando López¹, Javier Loricera², Carmen Secada³, Lucía García-Alcalde⁴, María Núñez-Savar⁴, Ander Ucelay-Aristi⁴ and Ricardo Blanco⁵, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, ⁴Department of Cardiovascular Surgery, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Aortitis is the inflammation of the aortic wall, and can be idiopathic or associated with a cluster of infectious and non-infectious diseases (1-3). Periaortitis,…
Abstract Number: 0713 • ACR Convergence 2023
IgG4-Related Disease as a Potencial Etiology of Idiopathic Constrictive Pericarditis
Edwin Ulises Cortez-Domínguez¹, Gabriela Hernandez-Molina¹, Norma Ofelia Uribe-Uribe², María J Lizardo-Thiebaud² and Eduardo Martin-Nares¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Constrictive pericarditis (CP) is a type of diastolic heart failure characterized by impaired cardiac filling due to the presence of an inelastic pericardium. Histologically,…
Abstract Number: 0714 • ACR Convergence 2023
Single Center Experience of Rituximab Treatment for IgG4-RD Disease in a Large Multi-ethnic Cohort
Matthew Colquhoun¹, Taryn Youngstein² and James Tomlinson³, ¹Department of Rheumatology, Imperial College Healthcare Trust, London, United Kingdom, ²National Heart & Lung Institute, Imperial College London, London, United Kingdom, ³Department of nephrology, Imperial College Healthcare Trust, London, United Kingdom
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibro-inflammatory disorder that can affect almost any organ system. Response to corticosteroids(CS) is typically prompt although adverse effects…
Abstract Number: 0715 • ACR Convergence 2023
Glucocorticoid Toxicity in Patients with IgG4-Related Disease Within the First Year of Treatment
Ana Mora-Rosas, Gabriela Hernandez-Molina, Edwin Ulises Cortez-Domínguez and Eduardo Martin-Nares, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Patients with IgG4-related disease (IgG4-RD) often require long-term glucocorticoid therapy. The prevalence, types, and underlying factors of glucocorticoid toxicity in IgG4-RD patients remain unknown.…
Abstract Number: 0716 • ACR Convergence 2023
Efficacy of Immunosuppressants for Disease Relapse in Patients with IgG4-related Disease at Our Institution
Kanako Chujo¹, Hiromi Shimada², Hiroki Ozaki³, Risa Wakiya⁴, Shusaku Nakashima⁴, taichi miyagi⁵, Yusuke Ushio⁶, Koichi Sugihara⁷, Mao Mizusaki⁴, Rina Mino⁸, Ryoko Kagawa⁹, Hayamasa Yamaguchi⁹, Tomohiro Kameda² and Hiroaki Dobashi², ¹Kagawa University, Miki, Kita District, Kagawa, Japan, ²Kagawa University, Kagawa, Japan, ³Department of Rheumatology, KKR Takamatsu Hospital, Kagawa, Japan, ⁴Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ⁵Kagawa university, Kidagun, Japan, ⁶Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, ⁷Kagawa University, Miki-cho, Kita-gun, Japan, ⁸Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan
Background/Purpose: Most patients with IgG4-related disease (IgG4-RD) have a good response to glucocorticoid (GC) therapy, however, disease relapses sometimes occur during GC tapering. Therefore, the…
Abstract Number: 1023 • ACR Convergence 2023
Characterization of Phenotypic Differences in IgG4-Related Disease Across the Sexes
Grace McMahon¹, Isha Jha¹, Aubree McMahon¹, Ana Fernandes¹, Zachary Wallace², Guy Katz¹, Cory Perugino¹ and John Stone³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a multi-organ fibroinflammatory disease with an autoimmune basis that can affect essentially any organ. Differences in phenotypic expression between males…
Abstract Number: 1131 • ACR Convergence 2023
Clinical Phenotypes of IgG4-related Disease in a Multi-ethnic Singapore Cohort
Choon Guan Chua¹, Weida Chew¹, Jeggrey Kay Wee Kam¹, Hwee-Pin Phua¹, Chengzi Chow¹, Carol Yee-Leng Ng¹, Wei-Yen Lim¹, Ru Sin Lim¹, Jereme Yijin Gan¹, Mung-Ee Loh¹, Tianrong Yeo², David Zhiwei Law¹, Stephrene Seok Wei Chan³, Amanda Francesca Ya-Fang Cheang⁴, Yong-Howe Ho¹ and Charles Kien-Fong Vu¹, ¹Tan Tock Seng Hospital, Singapore, Singapore, ²National Neurology Institute, Singapore, Singapore, ³National University Hospital, Singapore, Singapore, ⁴Woodlands Health Campus, Singapore, Singapore
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition that is heterogenous and can result in organ failure. To understand the disease profile of our local…
Abstract Number: 0128 • ACR Convergence 2022
Advantages of Alternate-Day Glucocorticoid Treatment Strategy for IgG4-Related Disease: A Preliminary Retrospective Study ID: 1287015
Sho Fukui¹, Takehiro Nakai², Satoshi Kawaai³, Yukihiko Ikeda², Masei Suda⁴, Atsushi Nomura⁵, Hiromichi Tamaki², Mitsumasa Kishimoto⁶, Sachiko Ohde⁷ and Masato Okada², ¹Kyorin University Hospital, Tokyo, Japan, ²St. Luke's International Hospital, Tokyo, Japan, ³St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ⁴Suwa Central Hospital, Nagano, Japan, ⁵St. Luke's International Hospital, Nagareyama, Japan, ⁶Kyorin University School of Medicine, Yokohama, Japan, ⁷Center for Clinical Epidemiology, St.Luke's International University, Tokyo, Japan
Background/Purpose: Alternate-day glucocorticoid (GC) treatment is an effective treatment option that can reduce GC-associated adverse events in patients with rheumatoid arthritis and other autoimmune rheumatic…
Abstract Number: 0144 • ACR Convergence 2022
The Association of Hypocomplementemia with Organ Involvement and Serum IgG4 in IgG4-related Disease
Guy Katz¹, Amelia S. Cogan¹, Grace McMahon¹, Sebastian Perez-Espina¹, Ana Fernandes¹, Cory Perugino¹, Zachary Wallace¹, John Atkinson², Alfred Kim² and John Stone³, ¹Massachusetts General Hospital, Boston, MA, ²Washington University School of Medicine, St. Louis, MO, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic immune-mediated disease that can affect nearly every organ in the body. Hypocomplementemia is common in some patients with…
Abstract Number: 0147 • ACR Convergence 2022
Rituximab in IgG4-Related Diseae: An Open-Label Non-Randomized Observational Study
Jens Vikse¹, Oyvind Midtvedt², Oyvind Molberg³, Bjørg Tilde Svanes Fevang⁴, Oyvind Palm², Torhild Garen², Katrine Brække Norheim⁵, Gunnstein Bakland⁶, Marianne Wallenius⁷ and Anna-Maria Hoffmann-Vold², ¹University of Bergen, Stavanger, Norway, ²Oslo University Hospital, Oslo, Norway, ³Oslo University Hospital, Oslo, Nepal, ⁴Haukeland University Hospital, Bergen, Norway, ⁵Stavanger University Hospital, Stavanger, Norway, ⁶University Hospital of North-Norway, Tromsø, Norway, ⁷St. Olav University Hospital, Trondheim, Norway
Background/Purpose: IgG4-related disease (IgG4-RD) is a rare, heterogenous and potentially severe disease. An open-label trial demonstrated efficacy of rituximab (RTX) in IgG4-RD. Recently, four distinct…

« Previous Page
1
…
3
4
5
6
7
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].